S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
The "King Of Quants" sees 10X potential... (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Factory or farm? Oregon may alter land use for chipmakers
The "King Of Quants" sees 10X potential... (Ad)
Travel disruption hits Germany on eve of transport strike
Berlin climate proposal fails to get enough yes votes to win
Fed's Shocking New Plan to Control Your Money (Ad)
Adele extends Las Vegas residency, plans concert film
Turkmenistan votes for new, opposition-free parliament
NASDAQ:KLDO

Kaleido Biosciences - KLDO Stock Forecast, Price & News

$0.0002
0.00 (0.00%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.0002
▼
$0.0002
50-Day Range
N/A
52-Week Range
$0.00
▼
$0.14
Volume
1,950 shs
Average Volume
13,721 shs
Market Capitalization
$8,524.60
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.70

Kaleido Biosciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
849,900.0% Upside
$1.70 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.27) to ($1.09) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

See Top Rated MarketRank™ Stocks Here

KLDO stock logo

About Kaleido Biosciences (NASDAQ:KLDO) Stock

Kaleido Biosciences, Inc. is a clinical-stage healthcare company, which engages in the provision of healthcare services. It focuses on leveraging the microbiome organ to treat disease and improve human health. The firm offers microbiome metabolic therapies (MMT), which are designed to modulate the metabolic output and profile of the microbiome by driving the function and composition of the organ's existing microbes. The company was founded by Geoffrey von Maltzahn and Noubar B. Afeyan on January 27, 2015 and is headquartered in Lexington, MA.

Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Stock News Headlines

December 17, 2022 | seekingalpha.com
KLDO Kaleido Biosciences, Inc.
November 10, 2022 | technews.tmcnet.com
VoLTE Roaming Readiness Ranked As High Priority For Mobile Operators: Kaleido Q3 2022 Mno Survey
March 26, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
September 27, 2022 | tmcnet.com
Syniverse Earns Industry Honors in Roaming and Data & Financial Clearing from Kaleido Intelligence
September 12, 2022 | benzinga.com
Airlinq, Tata Communications and Giesecke+Devrient, Recognised as Champion Cellular IoT Connectivity Vendors by Kaleido Intelligence
September 5, 2022 | benzinga.com
Exclusive Free Roaming Insights Available as Kaleido Becomes GSMA Member
July 26, 2022 | apnews.com
BCE To Provide $5 Billion Operator Revenue Opportunity From Permanently Roaming IoT Devices Over the Next 5 Years: Kaleido Intelligence
July 21, 2022 | msn.com
Ethereum’s Kaleido Collaborates With Polygon for Web3 Adoption
March 26, 2023 | Legacy Research (Affiliate) (Ad)
"Prepare for Five Years of Famine"
Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecast
June 14, 2022 | morningstar.com
Kaleido Biosciences Inc - Stock Price vs Fair Value KLDO
June 7, 2022 | tmcnet.com
Security and Design are the biggest knots to untangle, according to the largest-ever IoT connectivity survey run by Kaleido Intelligence
May 16, 2022 | uk.finance.yahoo.com
Kaleido Biosciences, Inc. (KLDO)
April 15, 2022 | seekingalpha.com
ATER, HNRG and AGLE among mid-day movers
April 8, 2022 | benzinga.com
Kaleido Biosciences Shares Halted On Code News Pending
April 8, 2022 | finance.yahoo.com
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
April 8, 2022 | msn.com
Flagship’s Kaleido Biosciences shuts down, as more biotechs lay off staff
April 8, 2022 | seekingalpha.com
Kaleido Biosciences to delist from Nasdaq as business operations end
April 8, 2022 | bizjournals.com
Kaleido Biosciences shuts down
April 1, 2022 | finance.yahoo.com
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
March 31, 2022 | finance.yahoo.com
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
March 25, 2022 | finance.yahoo.com
Bristol Myers (BMY) Gains 16% YTD: Will the Momentum Continue?
March 24, 2022 | finance.yahoo.com
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
March 16, 2022 | finance.yahoo.com
Radius Health Announces Leadership Appointments
March 15, 2022 | finance.yahoo.com
AnaptysBio's (ANAB) Acne Study on Imsidolimab Fails to Meet Goal
March 1, 2022 | finance.yahoo.com
Acadia (ACAD) Q4 Earnings & Revenues Fall Shy of Estimates
February 24, 2022 | finance.yahoo.com
Global Blood's (GBT) Q4 Earnings Miss Mark, Revenues Rise Y/Y
February 24, 2022 | finance.yahoo.com
Kaleido Biosciences, Inc. (KLDO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
See More Headlines
Receive KLDO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kaleido Biosciences and its competitors with MarketBeat's FREE daily newsletter.

KLDO Company Calendar

Last Earnings
11/01/2021
Today
3/26/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KLDO
CUSIP
N/A
CIK
1751299
Web
www.kaleido.com
Phone
(617) 674-9000
Fax
N/A
Employees
82
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$1.70
High Stock Price Forecast
$1.70
Low Stock Price Forecast
$1.70
Forecasted Upside/Downside
+849,900.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$1.10 million
Price / Sales
0.01
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
42,623,000
Free Float
38,787,000
Market Cap
$8,524.60
Optionable
Not Optionable
Beta
-0.06

Key Executives

  • Kimberly Hocknell
    Senior Vice President-Technical Operations

Key Competitors

View All Competitors













KLDO Stock - Frequently Asked Questions

Should I buy or sell Kaleido Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kaleido Biosciences in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KLDO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KLDO, but not buy additional shares or sell existing shares.
View KLDO analyst ratings or view top-rated stocks.

What is Kaleido Biosciences' stock price forecast for 2023?

1 equities research analysts have issued 1-year price targets for Kaleido Biosciences' shares. Their KLDO share price forecasts range from $1.70 to $1.70. On average, they anticipate the company's share price to reach $1.70 in the next year. This suggests a possible upside of 849,900.0% from the stock's current price.
View analysts price targets for KLDO or view top-rated stocks among Wall Street analysts.

How have KLDO shares performed in 2023?

Kaleido Biosciences' stock was trading at $0.0005 at the beginning of 2023. Since then, KLDO stock has decreased by 60.0% and is now trading at $0.0002.
View the best growth stocks for 2023 here.

When is Kaleido Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our KLDO earnings forecast.

How were Kaleido Biosciences' earnings last quarter?

Kaleido Biosciences, Inc. (NASDAQ:KLDO) released its quarterly earnings results on Monday, November, 1st. The company reported ($0.54) EPS for the quarter, meeting analysts' consensus estimates of ($0.54). The business earned $0.10 million during the quarter, compared to the consensus estimate of $0.25 million.

What other stocks do shareholders of Kaleido Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kaleido Biosciences investors own include Editas Medicine (EDIT), Alector (ALEC), Gossamer Bio (GOSS), Precision BioSciences (DTIL), Fulcrum Therapeutics (FULC), LogicBio Therapeutics (LOGC), Homology Medicines (FIXX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE) and Stoke Therapeutics (STOK).

When did Kaleido Biosciences IPO?

(KLDO) raised $101 million in an initial public offering (IPO) on Thursday, February 28th 2019. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Kaleido Biosciences' stock symbol?

Kaleido Biosciences trades on the NASDAQ under the ticker symbol "KLDO."

How do I buy shares of Kaleido Biosciences?

Shares of KLDO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kaleido Biosciences' stock price today?

One share of KLDO stock can currently be purchased for approximately $0.00.

How much money does Kaleido Biosciences make?

Kaleido Biosciences (NASDAQ:KLDO) has a market capitalization of $8,524.60 and generates $1.10 million in revenue each year.

How can I contact Kaleido Biosciences?

The official website for the company is www.kaleido.com. The company can be reached via phone at (617) 674-9000.

This page (NASDAQ:KLDO) was last updated on 3/26/2023 by MarketBeat.com Staff